Nystatin

證據等級: L5

預測適應症: 10 個

Nystatin: From Antifungal Therapy to Vulvovaginitis (Candida Vulvovaginitis)

One-Sentence Summary

Nystatin is a polyene antifungal agent whose established clinical role is treating Candida infections of the skin and mucous membranes; the specific original indication is not recorded in this evidence pack. The TxGNN model predicts it may be effective for Vulvovaginitis, and this direction is currently supported by 20 publications, though no dedicated clinical trials are registered for this specific indication.

Quick Overview

Item	Content
Original Indication	Not recorded in source data (no ARTG listing on file); Nystatin’s mechanism is that of a general topical/mucosal antifungal — see below
Predicted New Indication	Vulvovaginitis (Candida vulvovaginitis)
TxGNN Prediction Score	99.92%
Evidence Level	L3
Australia Market Status	Not marketed (not currently on the ARTG)
Number of ARTG Entries	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed, structured mechanism-of-action data was not available for this record (original_moa was not provided). However, the evidence pack’s own mechanistic analysis notes that Nystatin is a polyene antifungal that binds ergosterol in the fungal cell membrane, forming pores that cause leakage of cellular contents and lead to fungal cell death.

Candida albicans — the organism responsible for roughly 85–90% of vulvovaginal candidiasis cases per the literature below — is an ergosterol-dependent organism, i.e. exactly the molecular target Nystatin acts on. Vaginal nystatin (e.g. as vaginal tablets/pessaries) has in fact been used clinically for decades for this indication, so this prediction largely reflects a well-established, class-appropriate use rather than a novel repurposing signal.

Because the drug’s mechanism maps directly onto the pathogen driving vulvovaginitis, and because a substantial and long-running body of published literature already documents this use, the TxGNN prediction is biologically plausible and well corroborated — even though it may represent recovery of a known application rather than a genuinely new one.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
25775428	2015	Review	BMJ Clinical Evidence	Vulvovaginal candidiasis is the second most common cause of vaginitis after bacterial vaginosis; C. albicans accounts for 85–90% of cases
21774671	2011	Review	J Women’s Health	Discusses recurrent VVC management and rising azole resistance among non-albicans species, supporting alternative antifungals
4919155	1970	Review	Med Clin North Am	Classic clinical review of nystatin
16047929	2005	Cohort	Ceska Gynekologie	Evaluation of mixed/miscellaneous vulvovaginal infections treated with combined vaginal nifuratel + nystatin
12228137	2002	Review	BMJ	Overview of vulvovaginal candidiasis diagnosis and management
21718579	2010	Review	BMJ Clinical Evidence	VVC epidemiology; C. albicans accounts for 85–90% of cases
11363911	1996	Review	J Int Assoc Physicians AIDS Care	Review of candidiasis
39771534	2024	Review	Pharmaceutics	Update on management of fluconazole-resistant VVC; covers alternative antifungals including boric acid, nystatin, oteseconazole and ibrexafungerp
32104010	2020	In vitro	Infect Drug Resist	ZnO nanoparticles and nystatin downregulate SAP1-3 gene expression in fluconazole-resistant C. albicans isolates from VVC
19454049	2007	Review	BMJ Clinical Evidence	VVC epidemiology; C. albicans accounts for 85–90% of cases

Australia Market Information

Nystatin is not currently registered on the Australian Register of Therapeutic Goods (ARTG) — no product listings were found in the source data.

Safety Considerations

No TGA-approved Product Information exists for Nystatin in Australia, as it is not currently registered on the ARTG. Key warnings, contraindications and drug-interaction data were also not available from the sources queried for this evidence pack (DDI query returned no results). Safety information should be sourced from the manufacturer’s PI in a jurisdiction where the product is licensed before any clinical use is considered.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic link between Nystatin’s antifungal activity and the Candida-driven pathology of vulvovaginitis is strong and corroborated by a substantial literature base (L3, decision stage S2), but the prediction largely reflects an already-established use rather than a novel indication, and the drug currently has no Australian market presence or safety documentation on file.

To proceed, the following is needed:

Formal TGA-equivalent Product Information / safety labelling, since Nystatin is not currently on the ARTG (blocking gap per evidence pack)
Confirmed DrugBank-sourced mechanism-of-action documentation (currently marked as a data gap)
A complete drug-interaction (DDI) profile, as the current query returned no results
Clarification of whether this candidate represents a genuinely new indication or recovery of Nystatin’s known vaginal-antifungal label, to set appropriate expectations for any regulatory or clinical pathway
If market entry is pursued, an ARTG registration assessment given the current “not marketed” status in Australia
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.